Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Waste Management, Inc. (WM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Waste Management, Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while Waste Management, Inc. trades at $236 (market cap $95.26B). The key difference: Waste Management, Inc. is far larger — about 21.2× ACADIA Pharmaceuticals Inc.'s market cap, and Waste Management, Inc. pays a 1.49% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | WM | |
|---|---|---|
Market Cap | $4.49B | $95.26B |
Sector | Health | Industrials |
52-Week High | $28.06 | $246.51 |
52-Week Low | $20.06 | $196.77 |
Enterprise Value | $3.69B | $117.99B |
Dividend Yield | — | 1.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
WM trades at $237.21, up 2.96% today and near its 52-week high of $248.13. The stock shows bullish technical signals with strong moving averages and positive momentum indicators. Fundamentally, revenue grew to $25.20B in 2025 with a net income margin of 10.99%, though recent quarters saw mixed earnings results. Analyst consensus is bullish with a $261 price target, and the company maintains a solid dividend with recent payout of $0.95 per share.
Outlook remains positive driven by pricing discipline and renewable energy initiatives, but risks include elevated valuation multiples and debt levels. The stock offers stability through economic cycles but faces execution risks in maintaining margin growth amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Waste Management, Inc.
Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →
